Carbonic Anhydrase IX

Carbonic Anhydrase IX

Carbonic Anhydrase IX Overview

Molecule Name
Carbonic anhydrase IX
Synonyms
CAIX,CA9,CA-IX,G250,MN,P54,58N,pMW1
Drug Development Progress
Drugs in Clinical Trials16
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
EC:4.2.1.1,Renal cell carcinoma-associated antigen G250,P54/58N,CA9,Carbonic Anhydrase 9,RCC-Associated Protein G250,Carbonate Dehydratase IX,Carbonic Dehydratase,CA-IX,CAIX,PMW1,MN,EC 4.2.1.1,G250,Carbonic anhydrase IX,Membrane antigen MN,RCC-associated antigen G250
Background
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes. CAs form a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. One of the functions of the enzyme in animals is to interconvert carbon dioxide and bicarbonate to maintain acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. The active site of most carbonic anhydrases contains a zinc ion. There are at least five distinct CA families (α, β, γ, δ and ε). Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.

Carbonic Anhydrase IX Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Girentuximab MAb-G250; cG250; WX-G250Phase 3 ClinicalWilex AG
Carcinoma, Renal Cell; Kidney Neoplasms
Details
Girentuximab-Zr-8989Zr-TX250; TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TLX250Phase 3 ClinicalWilex AG
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Contrast agents; Esophageal Neoplasms; Glioblastoma; Nasopharyngeal Carcinoma; Sarcoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; von Hippel-Lindau Disease
Details
Lutetium-177 DOTA girentuximabTLX-250Phase 2 ClinicalHeidelberg Pharma AG, Telix Pharmaceuticals Ltd, Wilex AG
Carcinoma, Renal Cell; Neoplasms
Details
[177Lu]Lu-DPI-4452[177Lu]Lu-DPI-4452; Debio 0228; ITM-91; 3BP-4452; 177Lu-DPI-4452Phase 2 Clinical3B Pharmaceuticals GmbH
Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
Debio-0328[68Ga]Ga-DPI-4452; Gallium-68-DPI-4452; ITM-94D; 68Ga-DPI-4452Phase 2 Clinical3B Pharmaceuticals GmbH
Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
68Ga-NY10468Ga-NYM005; 68Ga-NY-104Phase 2 ClinicalWuxi Nuoyu Pharmaceutical Technology Co Ltd
Carcinoma, Renal Cell
Details
PMI-05PMI-05Phase 1 ClinicalPrecision Molecular Inc
Neoplasms
Details
PHC-10299mTc-CAIX; PHC102; 99mTc-PHC-102Phase 1 ClinicalPhilochem
Carcinoma, Renal Cell
Details
Indium-111-DOTA-girentuximab-IRDye800CW111In-girentuximab-F2Phase 1 ClinicalRadboud University Nijmegen
Carcinoma, Renal Cell; Diagnostic agents
Details
[211At]At-girentuximabPhase 1 ClinicalATONCO, Institut de Cancérologie de l'Ouest
Urinary Bladder Neoplasms
Details
[68Ga]Ga-OncoCAIX68Ga-OncoCAIX; [68Ga]Ga-OncoCAIXPhase 1 ClinicalPhilogen Spa
Carcinoma, Renal Cell
Details
18F-NY10418F-NY104; 18F-NYM005Phase 1 ClinicalWuxi Nuoyu Pharmaceutical Technology Co Ltd
Carcinoma, Renal Cell; Contrast agents
Details
CA9hu-1CA9hu-1Phase 1 ClinicalMabpro AS
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Mesothelioma; Triple Negative Breast Neoplasms
Details
Sulfamide-nitroimidazoleClinicalDualtpharma
Neoplasms
Details
68Ga-C1ClinicalThe First Affiliated Hospital Of Beijing University
Carcinoma, Renal Cell
Details
64Cu-PD-3276664Cu-PD-32766ClinicalPeptiDream Inc
Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details